IL1B and Parkinson disease: Accordingly, intra-nigral or systemic administration of LPS in PD murine models induces a central and peripheral pro-inflammatory status characterized by an increased release of damaging cytokines like TNF-α, IL-6 and IL-1, similar to what has been described in PD patients [17].